Treatment of Asthma : The long-acting beta-2-agonists /
The long-acting beta-2-agonists have become indispensible in modern asthma therapy. But do they have a fixed position in international guidelines? Here are the proceedings of the 6th Vienna Asthma Forum, when molecular biologists, drug designers, and clinicians discussed the role of three compounds...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Vienna :
Springer Vienna,
1998.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Collins, S., Wang, S.: Molecular regulation of the Beta2-adrenergic receptor by long- and short-acting Beta-agonists
- Adcock, I.M., Stevens, D.A.: Molecular interactions between glucocorticoids and Beta2-agonists
- Anderson, G.: Formoterol, a new long-acting Beta2-agonist
- Johnson, M.: Development of the long-acting Beta2-agonist, salmeterol
- Svensson, L.-A.: Development of bambuterol; a long-acting, orally active beta-agonist prodrug
- Gtz, M.: Development of beta-2 receptors in infancy and childhood
- Villiger, B.: Long-acting beta-agonists in exercise induced asthma
- Boyd, G.: Salmeterol and oral steroid treatment
- Greening, A.P.: Salmeterol and its relationship to treatment with inhaled corticosteroids
- Rudolf, M.: Long term treatment with Formoterol
- Selroos, O.: Comparison of efficiency of bambuterol and salmeterol
- Fabbri, M.L., Begh, B., Caramori, G., Ciaccia, A.: The future of relievers and controllers in asthma therapy.